Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LP 005

Next Previous
Drug Profile

LP 005

Alternative Names: LP-005

Latest Information Update: 24 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LongBio Pharma
  • Class Antibodies; Eye disorder therapies; Urologics
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal nocturnal haemoglobinuria
  • Phase I IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis
  • Preclinical Age-related macular degeneration; Amyotrophic lateral sclerosis; Blood dyscrasias; Kidney disorders; Myasthenia gravis

Most Recent Events

  • 23 Jan 2026 Longbio Pharma plans a phase II trial for Kidney disorders (Adjunctive therapy) in China (IV, Injection) in February 2026 (NCT07363265)
  • 09 Dec 2025 Longbio Pharma plans a phase II trial for Paroxysmal nocturnal haemoglobinuria in China (IV, Infusion) (NCT07266155) (CTR20254745)
  • 06 Dec 2025 Efficacy and adverse events data from a phase-II clinical trials in Paroxysmal nocturnal haemoglobinuria presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top